SCYNEXIS INC (SCYX) — SEC Financial Statements & Analysis

SCYNEXIS INC (SCYX) is a pharmaceutical preparations company. SCYNEXIS INC trades on Nasdaq as: SCYX. SCYNEXIS INC (SCYX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, SCYNEXIS INC carries a market cap of $48.12M, a P/E ratio of -4.70x, a P/B ratio of 0.72x, a P/S ratio of 2.50x, an enterprise value of $37.45M, and an EV/EBITDA multiple of -1.66x. On profitability, it posts a gross margin of 91.35%, an operating margin of -117.70%, a net margin of -53.27%, a Return on Equity (ROE) of -18.38%, a Return on Assets (ROA) of -15.09%, and a Return on Invested Capital (ROIC) of -50.31%. Per share, it reports EPS of $-0.87, diluted EPS of $-0.87, free cash flow per share of $-1.13, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 489.78% year-over-year, net income growth of -47.56% year-over-year, and EPS growth of -72.42% year-over-year. On the balance sheet, it maintains a current ratio of 9.65x, a quick ratio of 9.39x, working capital of $50.41M, a debt-to-equity ratio of 0.12x, a debt ratio of 0.11, an interest coverage ratio of -92.91x, free cash flow of $-13.31M (TTM), and net debt of $-10.68M. Figures sourced from SEC EDGAR.

Market Cap

$48.12M

P/E TTM

-4.70x

EPS TTM

$-0.87

P/B TTM

0.72x

ROE TTM

-18.38%

ROA TTM

-15.09%

Debt To Equity

0.12x

Free Cash Flow TTM

$-13.31M

Net Revenue TTM Growth 1Y

489.78%

Data as of 2026-06-30 · Source: SEC EDGAR